Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Needle-free intradermal Spikevax revaccination using nanoporous ceramic skin patch in healthy adults
2021-006754-31Phase 2Active
- Sponsor
- Leiden University Medical Center
- Start
- Feb 2022
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of elasomeran in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Leiden University Medical Center. Primary endpoint: Safety of intradermal Spikevax via ceramic skin patch vs intramuscular administration. Started Feb 2022; status: active.
02
Drugs
elasomeran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2021-006754-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006754-31.